SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Pharmova jumps on entering into agreements to acquire stake in SPV Laboratories

04 Apr 2022 Evaluate

Jubilant Pharmova is currently trading at Rs. 435.20, up by 25.50 points or 6.22% from its previous closing of Rs. 409.70 on the BSE.

The scrip opened at Rs. 417.60 and has touched a high and low of Rs. 437.15 and Rs. 413.45 respectively. So far 23034 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 925.00 on 27-May-2021 and a 52 week low of Rs. 384.85 on 31-Mar-2022.

Last one week high and low of the scrip stood at Rs. 437.15 and Rs. 384.85 respectively. The current market cap of the company is Rs. 6865.02 crore.

The promoters holding in the company stood at 50.68%, while Institutions and Non-Institutions held 24.24% and 25.08% respectively.

Jubilant Pharmova has entered into Share Purchase agreement, and Share Subscription and Shareholders agreement on April 1, 2022 for acquiring equity and preference shares of SPV Laboratories (Greencure). Greencure products have differentiated positioning, combining the best of Ayurveda and German herbal science.

The company has obtained multiple international certifications to strengthen their credibility. The market is being driven by a growing shift towards natural products, as well as rise in chronic diseases and growing health awareness. There is also a strong synergy between Jubilant and Greencure with respect to OTC portfolio which can be explored for R&D, online acceleration and offline distribution. Aggregate cost of acquisition is Rs 8.75 crore for acquiring 25.21% stake.

Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.



Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×